increas fair valu per share
updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim jan
price data feb
rate updat feb
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
vertex known discov incivek blockbust
hepat drug overshadow vertex robust cystic
fibrosi franchis megablockbust potenti approv
treatment kalydeco orkambi symdeko trikafta make
vertex elig treat cf popul assum
intern pediatr approv expect vertex
maintain domin posit cystic fibrosi given strong
efficaci therapi lengthi patent lack competit
develop pipelin candid rare indic
cystic fibrosi rare indic character progress
deadli declin lung function affect approxim
peopl world-wide sinc launch kalydeco captur
target patient popul less cf patient
specif genet mutat becom backbon
combin therapi includ orkambi symdeko trikafta
orkambi launch expand elig patient popul
ad cf patient homozyg mutat
uptak slower safeti profil symdeko
launch didnt come worri safeti contribut
million revenu first year target
popul orkambi plu trikafta tripl combin
therapi approv octob significantli grow
compani address patient popul heterozyg
think vertex comprehens approach alreadi shape
treatment cf earn firm domin posit
market world-wide chronic natur therapi limit
competit horizon heighten market attract
given posit market dynam think vertex cf
program could grow billion within forecast period
early-stag pipelin span sever rare diseas includ
beta-thalassemia sickle-cel diseas well
least one disclos earli candid antitrypsin
defici think cf franchis provid ampl cash
futur develop asset other
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
discov develop small-molecul drug
treatment seriou diseas key drug kalydeco orkambi
symdeko trikafta cystic fibrosi vertex therapi remain
standard care global vertex pipelin also includ therapi
cancer pain inflammatori diseas influenza rare diseas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
increas fair valu estim
per share vertex outperform expect
launch trikafta tripl combin contribut
million first quarter launch pois
continu solid growth throughout explicit
key driver valuat growth come
continu ramp-up symdeko tezacaftor kalydeco
trikafta
expect billion cystic fibrosi sale
driven symdeko homozyg patient
trikafta homozyg heterozyg
patient vertex complet portfolio cystic fibrosi
therapi allow target cystic fibrosi
patient global think cystic fibrosi sale
climb billion
pipelin contribut nearli million sale
mani compani pipelin asset earli stage
low probabl approv opportun includ
gene therapi beta thalassemia sickl cell
diseas well antitrypsin defici
also expect compani continu fund research
cystic fibrosi develop next-gener small molecul
corrector eventu gene therapi
assum oper expens grow midsingl
digit throughout forecast vertex continu cystic
fibrosi commerci strategi push pipelin
clinic trial robust product sale expand
oper margin past compar
due strong posit cystic fibrosi off-set
vulner potenti competit bull case
model higher probabl approv vertex pipelin
includ gene therapi candid blockbust
potenti rare indic assum trikafta
gain share quickli heterozyg popul
scenario mid-cycle sale surpass billion
compani oper margin bull-cas
fair valu estim
bear case assum trikafta face competit
price headwind lower sale assumpt cf
scenario mid-cycle sale billion
oper margin approxim bear-cas fair
valu estim
throughout explicit
vertex portfolio patent-protect cystic fibrosi
first-mov statu rare indic signific
patient share believ like
vertex abl earn excess return next
symdeko trikafta disease-modifi drug
market portfolio make backbon cystic
fibrosi therapi support strong price power
intang asset key moat sourc vertex
compani benefit patent protect
cystic fibrosi therapi vertex abl build upon
intellectu properti roll better medicin
combin increasingli captur patient
kalydeco approv cf patient one copi
mutat quickli pick label expans
addit mutat age group expand
elig patient popul patient
 first approv orkambi
approv patient two copi
common mutat expand elig patient
popul significantli global
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
backbon treatment option
cystic fibrosi rare chronic condit without
command strong price power mani patient start
treatment earli childhood continu lifetim
estim kalydeco vertex first cf therapi
list price monotherapi target
cf patient orkambi symdeko
doublet treat much larger portion cf patient
far behind six-figur price tag trikafta
list price launch reach exhibit
compani strong price power strong efficaci
price power vertex cystic fibrosi portfolio
potenti contribut billion sale
compar billion
vertex face signific competit cystic
fibrosi market opinion galapago partnership
previous closest competitor
report lacklust phase result lead candid
illustr high bar efficaci vertex portfolio
led partner initi step away
trial acquir galapago cf pipelin
octob still unclear intent
candid see viabl threat
competitor proteostasi doublet
triplet well one candid combin
vertex therapi report disappoint data
first quarter sever year behind vertex
believ vertex benefit posit moat trend
rate base recent approv promis pipelin
like support domin posit cystic
fibrosi compani demonstr lucr
develop strategi build upon kalydeco
doublet orkambi symdeko well trikafta
tripl combin next five year estim
end symdeko approv target
patient popul orkambi help vertex captur
addit patient share due better efficaci final
trikafta approv expand
popul trikafta potenti approv
abroad pediatr patient think elig
patient popul reach roughli
cf patient
vertex strategi build upon kalydeco symdeko
orkambi doublet combin add cftr
corrector kalydeco cftr potenti trikafta
tripl combin build molecul symdeko
kalydeco layer new cftr corrector elexacaftor
trikafta deliv promis data rapidli achiev
regulatori approv octob us uniqu
mechan therapi addit molecul
result new efficaci therapi serv
competit advantag vertex entrench
therapi cystic fibrosi treatment lengthen
period patent protect mani pipelin competitor
studi candid combin one
vertex molecul illustr vertex posit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
compani could treat elig patient
patient share increas driven symdeko approv
trikafta approv revenu
growth trikafta add posit trend rate
new combin lengthen possibl patent protect
lack close competit also support
posit trend rate give vertex room take tripl
combin across finish line thu significantli
expand elig patient popul includ
cystic fibrosi patient
given earli statu assign much weight
opportun earli pipelin candid focu
beta-thalassemia sickle-cel diseas line
compani core focu later-stag candid
oncolog partner merck influenza partner
johnson johnson pain look promis
would add diversif vertex strengthen base
intang asset
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ocyst fibrosi main driver vertex valuat
compani could fail diversifi
opric pressur could erod return given high
price tag vertex therapi
ogene-edit program could disrupt vertex hold
cystic fibrosi market
oth firm cystic fibrosi therapi pois
domin lucr market forese
futur base disease-modifi potenti
drug chronic use patient limit
lead drug candid mostli
discov in-hous lend credibl drug-
discoveri technolog potenti gener
overtex combin therapi lengthi patent
protect profit cystic fibrosi portfolio
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
believ vertex strong financi health given
robust cash flow gener reason debt
year-end vertex billion cash
invest million debtlik leas
oblig like biotechnolog compani earli
stage vertex histor oper loss
high cost clinic trial research loss
financ larg offer equiti
develop mileston
partner howev launch orkambi
kalydeco compani abl gener
signific revenu allow build signific
cash cushion suffici fund develop
commerci remain development-stag
candid launch symdeko trikafta
believ compani continu oper sustain
profit level throughout explicit forecast expect
vertex mostli use cash build
diversifi rare-diseas portfolio look beyond
believ vertex merit medium uncertainti rate
lack diversif off-set strong posit
cystic fibrosi lack competit compani
valuat driven cystic fibrosi franchis growth
larg depend tripl combin success
price power fair level uncertainti
think lack close competit
strong cash gener medium term provid solid
cushion risk relianc cystic fibrosi
assumpt high price underpin view
blockbust potenti cf market risk
price pressur payer particularli stricter regul
europ depress return despit vertex strong posit
competit nation health servic england
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
deni reimburs orkambi sinc approv
cite cost-effect concern howev
believ wide public battl orkambi
reimburs unit kingdom outlier
benefit match altern form
care risk investor awar
potenti competit compani earli pipelin
competit cystic fibrosi still fairli spars
small risk disrupt gene edit
vertex therapi disease-modifi
correct underli genet mutat howev vertex
partner crispr uncov cure year
expertis indic pipelin success especi
rare diseas orphan drug strong price
power would provid welcom diversif firm
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund growth fund amer
capit research manag compani
share
fund
share
fund
stewardship rate although compani leadership
team transit follow announc
jeffrey leiden step ceo take role
execut chairman
jeffrey leiden becam ceo chairman
experi includ role manag director claru
ventur special life scienc capit well
presid chief oper offic abbott
laboratori experi pharma shone
brought vertex cash-burn stage
emerg biotech larg lead biotech firm
expans franchis cystic fibrosi therapi
former chief medic offic dr reshma kewalramani
take ceo role april join vertex
kewalramani spent decad
believ well-suit lead vertex expand
rest manag team compos
pharma veteran adequ level experi
view previou cfo ian smith abruptli termin
earli person behavior detail
disclos reason believ
significantli weigh compani stewardship
think manag compens histor
high although recent measur spur sharehold
vote curtail amount go forward
leiden total compens million sever
senior manag compens packag
million leiden total compens drop
million respons sharehold disapprov
drop million compani also probe
secur exchang commiss seri
larg insid stock sale posit clinic news past
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
increas vertex fve strong promis
outlook cystic fibrosi beyond jan
expect mid- high single-digit increas
fair valu estim narrow-moat vertex follow
biotech strong fourth-quart result manag
guidanc compani lead posit cystic
fibrosi therapi basi narrow econom moat
rate cement ahead-of-schedul
approv trikafta octob trikafta launch
surpass expect fourth quarter partial
help launch-rel inventori build roughli
million contribut million sale vertex
seen strong interest trikafta patient group
includ patient alreadi exist vertex therapi
full-year adjust oper incom nearli billion
last year total revenu
billion last year cf drug trikafta
symdeko drive top-lin growth fourth quarter
surpris see rapid rate convers
older vertex cf therapi kalydeco orkambi symdeko
trikafta plan adjust model account
faster-than-expect convers trikafta lift
sale estim substanti trikafta price
point rel vertex therapi
switch trikafta illustr drug attract profil
demonstr high bar futur competitor
includ eventu gener expect vertex
abl defend domin posit cf brand
gener competit thank long patent live
portfolio expertis indic continu
invest search next-gener therapi
look catalyst year look forward
see data vertex early-stag asset mark
compani key opportun pivot new diseas
area outsid cf anticip earli data
small molecul alpha-on antitrypsin defici
well addit data vertex crispr
therapeut gene therapi sickl cell diseas
beta thalassemia demonstr posit result
two patient late approv rare indic
high unmet need would solidifi vertex
competit posit narrow moat
last sever month mark sever key
achiev narrow-moat
cystic fibrosi franchis clinch key approv trikafta
triplet combin compani also
final land reimburs agreement england
three-year stalem negoti price
vertex third-quart result solid well
million revenu last year within
expect howev expens tick significantli
particularli research develop spend relat
pipelin make near-term adjust
model hold fair valu estim per
share maintain narrow moat rate support
compani domin posit cystic fibrosi
key question face vertex pivot
major cystic fibrosi patient access
treatment compani vertex made
commend progress build pipelin spend
billion cash year date busi
develop acquisit partnership
result sever program on-going
give mani early-stag candid credit
model yet compani pois see signific
upsid pipelin success
later year compani plan start phase
trial antitrypsin defici addit
on-going phase trial indic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
compani believ cf franchis continu
drive strong return vertex approv trikafta
allow vertex treat larg portion cf patient
therapi abl address
compos patient one mutat one
vertex address patient popul
peopl intern pediatr approv
trikafta futur vertex elig provid
treatment cf popul
total sale compani cf franchis could
individu overal think sale
although know firm continu work
cf treatment next-gener
therapi also watch see
compani focu shift key approv
belt new ceo take helm april
includ beta-thalassemia sickle-cel
diseas well least one disclos earli candid
antitrypsin defici
defici similar cystic fibrosi mani way
genet diseas caus protein misfold
prove effect vertex two small molecul corrector
opportun serv patient
 europ
also year look forward data phase
studi gene edit therapi sickl cell
diseas beta thalassemia vertex develop
partnership across
europ opportun treat
patient sickl cell diseas beta
thalassemia howev
indic
competitor pipelin
approv vertex pois cover cf popul
oct food drug administr approv
narrow-moat vertex tripl combin therapi cystic
fibrosi cf market trikafta
believ trikafta strong chanc approv base
trial data acceler timelin approv
five month ahead target action date caught us
guard compani vast network cf patient
doctor think compani hit ground run
commerci effort made near-term
adjust add million revenu
trikafta bring total cf sale
billion line manag new guidanc
billion addit drug list price disclos
per year slightli higher
anticip increas assumpt net price
 previou estim
per year small chang materi
affect fair valu estim hold steadi
per share
approv solidifi narrow moat rate
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
